Filter by: Subject

Filter by: Subject

Results Per Page:

Multidrug-resistant tuberculosis (MDR-TB) (5)
Bedaquiline (4)
Human immunodeficiency virus (HIV) (4)
Clofazimine (3)
Drug-resistant tuberculosis (DR-TB) (3)
Extensively drug-resistant tuberculosis (XDR-TB) (3)
Clofazimine (CFZ) (2)
Drug susceptibility testing (DST) (2)
Epidemics (2)
Genome (2)
Linezolid (2)
MDR-TB (2)
Minimum inhibitory concentrations (MIC) (2)
Molecular detection (2)
Multidrug-resistant (MDR) (2)
Mutation (2)
Patients (2)
Rifampicin (2)
Transmission (2)
XDR-TB (2)
960™ (1)
Acid-fast bacilli (AFB) (1)
Acquired immune deficiency syndrome (AIDS) (1)
Adults (1)
Africa (1)
Anti-tuberculosis drugs (1)
Antibiotic-resistant (1)
Antimicrobial resistance (AMR) (1)
Antituberculosis therapy (1)
Anyplex™ plus (1)
Area under the curve (1)
AtpE mutations (1)
BACTEC MGIT 960 (1)
Bacteria (1)
Bedaquiline (BDQ) (1)
Biological marker (1)
CD4+ T lymphocyte (1)
Critical concentration (CC) (1)
Cross-resistance (1)
Culture conversion (1)
Cut-off value (ECV) (1)
Detection (1)
Detection system (1)
Disease severity (1)
DNA stability (1)
Draft genome sequence (1)
Drug resistant tuberculosis (DR-TB) (1)
Drug sensitivity (1)
Drugs (1)
Efflux pump mutants (1)
Flow cytometry (1)
Fluoroquinolone (1)
Fluoroquinolones (FLQ) (1)
Genetic sequencing (1)
GenoType MTBDRplus (1)
GenoType MTBDRsl version 2.0 (1)
Genotype® MTBDRsl (1)
Genotypic analyses (1)
High HIV prevalence setting (1)
HIV/AIDS (1)
Human (1)
Immunoassay (1)
In vitro (1)
In vitro model (1)
Infectious diseases (1)
Ion torrent (1)
Isoniazid (1)
Isoniazid mono-resistant tuberculosis (1)
Ki 67 antigen (1)
KwaZulu-Natal (KZN) (1)
KwaZulu-Natal, South Africa (1)
Line probe assay (LPA) (1)
Lung cavities (1)
MGIT™ (1)
Microbiological examination (1)
Microscopy (1)
Minimal inhibitory concentrations (MIC) (1)
Minimum inhibitory concentration (1)
Molecular assays (1)
Molecular diagnostic testing (1)